Read more

All materials related to the From Testing to Targeted Treatment Programme


Geraldine Reilly

Global Patient Engagement lead Gilead Science at Gilead Sciences

United Kingdom

Gilead Sciences

Nicola Bedlington

Secretary General at European Patients' Forum

Brussels, Belgium

European Patients' Forum (EPF) / PFMD / EUPATI

Quentin Clermont

COO at The Synergist

The Synergist

Nicholas Brooke

PFMD Executive Director

Bruxelles, Belgium

The Synergist / PFMD

Pledge icon

Lise Brooke

Communications Coordinator - The Synergist

The Synergist

Nicole Wicki

Program Manager at The Synergist


The Synergist / PFMD / From Testing to Targeted Treatments (FT3)

Silvia Bornengo

Program Coordinator

The Synergist / PFMD / From Testing to Targeted Treatments (FT3)

Rebecca Vermeulen

Head Global Medical Liaisons and Communications

F. Hoffmann La Roche

Marc Boutin

Global Head of Patient Engagement & Advocacy

United States


Sanja Njegic

Global Head Patient Partnership

F. Hoffmann La Roche


Durhane Wong-Rieger

President & CEO

Toronto, Canada

Canadian Organization for Rare Disorders / From Testing to Targeted Treatments (FT3)

Jeanne Regnante

Senior Vice President, Patient Engagement & Chair, Diverse Communities WG

United States

Sustainable Healthy Communities, LLC (SHC)



  From Testing to Targeted Treatments (FT3) Program


The Immuno-oncology Portal (IOP)

21 Jan 2021 Learning and training

A Consumer's Guide to Genetic Health Testing

14 Aug 2020 Framework/guidance

What is personalised healthcare in cancer care?

14 Aug 2020 Framework/guidance

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations.

14 Aug 2020 Publication